3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Colorectal Neoplasms
6
Carcinoma, Hepatocellular
4
Sarcoma
2
Rectal Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Gastrointestinal Stromal Tumors
2
Solid Malignant Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Piebaldism
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Glioblastoma
1
Disease Progression
1
Cholangiocarcinoma
1
Bone Neoplasms
1
Interventions
Doxorubicin
13
Specimen Handling
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
Cyclophosphamide
9
X-Rays
7
Ifosfamide
7
Radiotherapy
6
Phantoms, Imaging
6
Gemcitabine
6
liposomal doxorubicin
5
Nivolumab
5
tazemetostat
4
palbociclib
4
fludarabine
4
atezolizumab
4
Temozolomide
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
larotrectinib
3
cabozantinib
3
Surveys and Questionnaires
3
Ipilimumab
3
Carboplatin
3
Bevacizumab
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Sarcoma
×
regorafenib
×
90 days
×
Clear all
NCT03793361
2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2
Completed
127 enrolled
NCT01900743
2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2
Completed
219 enrolled